2.80
price up icon3.32%   0.09
after-market Handel nachbörslich: 2.80
loading

Lite Strategy Inc Aktie (LITS) Neueste Nachrichten

pulisher
Sep 18, 2025

MEI PHARMA, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K) - MarketScreener

Sep 18, 2025
pulisher
Sep 16, 2025

Lite Strategy: From Biotech To Litecoin Treasury (NASDAQ:LITS) - Seeking Alpha

Sep 16, 2025
pulisher
Sep 15, 2025

Lite Strategy Investor Exercises Warrants in Cashless Deal - TipRanks

Sep 15, 2025
pulisher
Sep 15, 2025

Lite Strategy with New NASDAQ Ticker ‘LITS’ Enters the Public Market - CryptoNinjas

Sep 15, 2025
pulisher
Sep 13, 2025

LITS Stock Price and Chart — NASDAQ:LITS - TradingView

Sep 13, 2025
pulisher
Sep 11, 2025

MEI Pharma, Inc will Change its Name to Lite Strategy, Inc - MarketScreener

Sep 11, 2025
pulisher
Sep 10, 2025

MEI Pharma Rebrands to Lite Strategy, Inc. - TipRanks

Sep 10, 2025
pulisher
Sep 10, 2025

MEI Pharma rebrands as Lite Strategy, adopts Litecoin as treasury asset - Investing.com

Sep 10, 2025
pulisher
Sep 10, 2025

MEI Pharma rebrands as Lite Strategy, adopts Litecoin as treasury asset By Investing.com - Investing.com Nigeria

Sep 10, 2025
pulisher
Sep 10, 2025

MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’ - Business Wire

Sep 10, 2025
pulisher
Aug 22, 2025

Lite Access Technologies Expands Through Strategic Acquisition of Ironman - MSN

Aug 22, 2025
pulisher
Aug 05, 2025

MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising - Business Wire

Aug 05, 2025
pulisher
Jul 22, 2025

MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange - Business Wire

Jul 22, 2025
pulisher
Jul 18, 2025

Biotech Pioneer Converts $100M Treasury to Litecoin as Charlie Lee Joins Board - Stock Titan

Jul 18, 2025
pulisher
Jul 15, 2025

Damon CEO Showcases Asset-Light Strategy, HyperSport Development, and Revolutionary Damon™ I/O Platform in WebBikeWorld Feature Article - Yahoo Finance

Jul 15, 2025
pulisher
Jul 10, 2025

NUBURU Stockholders Green-Light Strategy to Finance Transformation in Key Stockholder Vote - Yahoo Finance

Jul 10, 2025
pulisher
May 27, 2025

Lennar De-Risking Portfolio Through Strategic Shift - Forbes

May 27, 2025
pulisher
May 19, 2025

Clorox's Innovations on Track: Kingsford & Miller Lite Bring Beercoal - Yahoo Finance

May 19, 2025
pulisher
May 13, 2025

MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position - Business Wire

May 13, 2025
pulisher
Apr 14, 2025

Navigating Retail and Specialty Lite Success: How Your Pharmacy Strategy Impacts Brand Performance - Fierce Pharma

Apr 14, 2025
pulisher
Apr 04, 2025

Centurion Corp Poised for Continued Growth with Expanding Pipeline and Asset-Light Strategy - Minichart

Apr 04, 2025
pulisher
Mar 05, 2025

From ‘Aisle to Algorithm': David's Bridal Unveils Digital-First Transformation to Become Wedding Industry's Leading Retailer and Media & Planning Marketplace - Newswire.com

Mar 05, 2025
pulisher
Feb 28, 2025

Focus on an ‘asset-light’ strategy reason why Melco Resorts considers options for City of Dreams Manila: Lawrence Ho - GGRAsia

Feb 28, 2025
pulisher
Dec 26, 2024

Sharp advances asset-light strategy with US$159.06 million sale to Sekisui Chemical - digitimes

Dec 26, 2024
pulisher
Dec 20, 2024

Is CapitaLand’s Asset-Light Strategy Losing Its Shine? - Minichart

Dec 20, 2024
pulisher
Dec 17, 2024

Lite Bite Foods in talks to sell minor stake to strategic investors - The Economic Times

Dec 17, 2024
pulisher
Nov 23, 2024

Lennar: A Solid Investment With Its Land-Light Strategy - Seeking Alpha

Nov 23, 2024
pulisher
Nov 12, 2024

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position - MarketScreener

Nov 12, 2024
pulisher
Oct 29, 2024

How asset-light business models can boost financial performance - EY

Oct 29, 2024
pulisher
Sep 24, 2024

Jim Cramer on Starbucks Corporation (SBUX): ‘Will Starbucks Adopt A So-Called China Lite Strategy Under New CEO Brian Niccol?’ - Yahoo Finance

Sep 24, 2024
pulisher
Sep 19, 2024

MEI Pharma Reports Fiscal Year End 2024 Cash Position - Business Wire

Sep 19, 2024
pulisher
Aug 12, 2024

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives - MarketScreener

Aug 12, 2024
pulisher
Jul 01, 2024

An Post: New Green Light 2028 strategy will grow company to a €1bn business - Post & Parcel

Jul 01, 2024
pulisher
May 14, 2024

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP) - MarketScreener

May 14, 2024
pulisher
Apr 15, 2024

High-end hotels and asset light model suit Hyatt strategy - Hospitality Investor

Apr 15, 2024
pulisher
Apr 02, 2024

By Light Announces Strategic Market Expansion into the United Kingdom - Send2Press

Apr 02, 2024
pulisher
Feb 10, 2024

Minor uses asset-light strategy - bangkokpost.com

Feb 10, 2024
pulisher
Nov 01, 2023

MEI Pharma, Inc. Announces Board Changes - MarketScreener

Nov 01, 2023
pulisher
Jul 23, 2023

MEI Pharma Announces Results of Special Meeting of Stockholders - MarketScreener

Jul 23, 2023
pulisher
Jul 11, 2023

MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals - MarketScreener

Jul 11, 2023
pulisher
Jun 13, 2023

Mei Pharma, Inc. Announces Executive Changes - MarketScreener

Jun 13, 2023
pulisher
Jun 02, 2023

MEI Pharma, Inc. Announces Executive Changes - MarketScreener

Jun 02, 2023
pulisher
Apr 14, 2023

MEI Pharma Announces 1-for-20 Reverse Stock Split - Business Wire

Apr 14, 2023
pulisher
Feb 23, 2023

MEI Pharma, Inc. Announces Management Changes - MarketScreener

Feb 23, 2023
pulisher
Jan 06, 2023

MEI PHARMA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) - MarketScreener

Jan 06, 2023
pulisher
Oct 27, 2022

MEI Pharma, Inc. Announces Not Stand for Re-Election of Directors - MarketScreener

Oct 27, 2022
pulisher
Jun 10, 2022

MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress - MarketScreener

Jun 10, 2022
pulisher
Jun 04, 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022 - MarketScreener

Jun 04, 2022
pulisher
Feb 07, 2022

MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments - MarketScreener

Feb 07, 2022
pulisher
Jan 25, 2022

CANOmni-Lite Industries Announces Strategic Acquisition of Designed Precision Castings Following the Completion of the Sale and Leaseback of the Company’s California Real Estate Assets - foundry-planet.com

Jan 25, 2022
pulisher
Jan 10, 2022

MEI Pharma : January 2022 Corporate Presentation - MarketScreener

Jan 10, 2022
pulisher
Jan 03, 2022

MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Jan 03, 2022
pulisher
Jul 07, 2021

MEI Pharma, Inc. Appoints Tina C. Beamon, J.D., as Chief Compliance Officer - MarketScreener

Jul 07, 2021
pulisher
Apr 30, 2021

MEI Pharma : Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer - MarketScreener

Apr 30, 2021
pulisher
Jan 05, 2021

MEI Pharma : Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update - MarketScreener

Jan 05, 2021
pulisher
Dec 14, 2019

Infineon affirms move to ‘fab-lite’ strategy - EE Times

Dec 14, 2019
pulisher
Feb 26, 2018

MEI Pharma Appoints Frederick W. Driscoll to Board of Directors - MarketScreener

Feb 26, 2018
pulisher
Sep 02, 2016

MEI Pharma, Inc. Announces Resignation of Leah Rush Cann as Member of the Board - MarketScreener

Sep 02, 2016
pulisher
Apr 04, 2015

Analyzing Starwood’s Asset-Light Strategy - Market Realist

Apr 04, 2015
pulisher
Feb 11, 2013

MEI Pharma, Inc. Appoints Thomas C. Reynolds to its Board of Directors - MarketScreener

Feb 11, 2013
$36.24
price up icon 1.43%
$86.53
price up icon 0.62%
$28.28
price up icon 0.86%
$96.22
price down icon 0.09%
$144.76
price down icon 0.75%
biotechnology ONC
$334.40
price down icon 2.48%
Kapitalisierung:     |  Volumen (24h):